Illumina, Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Illumina, Inc. trades at $277.61 (market cap $39.95B), while State Street Technology Select Sector SPDR ETF trades at $198.92 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 3.3× Illumina, Inc.'s market cap, and State Street Technology Select Sector SPDR ETF is more actively traded (9,063,135 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| ILMN | XLK | |
|---|---|---|
Market Cap | $39.95B | $132.55B |
Volume | 3,169,503 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $293.69 | $202.00 |
52-Week Low | $91.00 | $127.49 |
Typical Hold Time | 83 Days | 50 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
XLK trades at $198.68, down 1.35% on the day, with technical indicators showing a bullish overall signal driven by strong moving average support. The ETF maintains neutral oscillators with RSI readings around 60, suggesting balanced momentum. Recent news highlights ongoing investor focus on AI sector dynamics and concentration concerns within XLK's holdings, particularly its heavy chip exposure that may limit diversification benefits despite quarterly rebalancing.
The outlook for XLK remains tied to technology sector performance and AI investment trends, with potential upside from continued enterprise software strength and semiconductor demand. Key risks include interest rate sensitivity, sector concentration, and competitive ETF alternatives offering better risk-adjusted returns. Investors should weigh XLK's cost efficiency against its mega-cap heavy structure when considering technology exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →